Creso Pharma has purchased Mernova Medicinal for C$10.1m ($8.08m) through its Canadian subsidiaries Creso Canada and Creso Canada Corporate.

The acquisition involved three milestone cash payments of C$1.8m ($1.44m) along with issue of Creso’s shares valued at C$8.3m ($6.64m) based on achievement of milestones.

Creso Pharma will pay C$0.2m ($0.16m) in cash and issue 8.3 million exchangeable shares of Creso Canada to Mernova’s shareholders, upon completion of the transaction.

Based in Australia, the acquirer company is a cannabis-derived, therapeutic-grade nutraceutical products provider, while the target company is a Canadian manufacturer of medicinal cannabis.

The acquisition will enable Creso Pharma to enter the Canadian medicinal and recreational cannabis market.

Mundipharma has acquired Tolmar Australia, along with exclusive distribution rights to the latter’s hormonal therapies Eligard (leuprorelin acetate) and Bi-Eligard in Australia and New Zealand.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Both companies involved in the transaction are pharmaceutical companies based in Australia.

“Roche has signed an agreement to purchase the remaining equity of US-based healthcare technology Flatiron Health for $1.9bn.”

The acquisition will expand Mundipharma’s oncology portfolio.

Roche has signed an agreement to purchase the remaining equity of US-based healthcare technology Flatiron Health for $1.9bn.

The transaction will increase Roche’s share in the target company to 100% from the existing 12.6%.

The acquisition will help the acquirer company, a healthcare company based in Switzerland, to develop and supply innovative medicines for cancer patients.

HGL has signed an agreement to purchase a 70% stake in Pegasus Healthcare for A$4.45m ($3.51m).

HGL will work in partnership with Pegasus Healthcare’s CEO Scott Nowland, who owns the remaining 30% stake in the company.

The acquisition is expected to be closed in March 2018.

HGL is involved in the import and distribution of branded products for specialist markets, while Pegasus Healthcare supplies clinically proven products for pressure ulcers in the acute and residential care sectors.

Both companies involved in the transaction are based in Australia.